FBIO has more cash than debt and preferred stock. Consolidated balance sheet cash has grown to $171 million.
FBIOP is a par $25 preferred stock issue that now trades for only $20.45.
FBIOP offers an 11.7% yield and the potential for capital gain of almost 25% if the price recovers to trade at par.
FBIO is a diverse biotech incubator that controls three public early stage biotechs as well as six private ones.